Operating Profit Margin
since 2018
Calculation
Moderna Inc., operating profit margin, long-term trends, calculation
| Operating profit margin | = | 100 | × | Income (loss) from operations1 | ÷ | Product sales1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2022 | 51.10% | = | 100 | × | 9,420) | ÷ | 18,435) |
| Dec 31, 2021 | 75.22% | = | 100 | × | 13,296) | ÷ | 17,675) |
| Dec 31, 2020 | -381.82% | = | 100 | × | (763) | ÷ | 200) |
| Dec 31, 2019 | — | = | 100 | × | (546) | ÷ | —) |
| Dec 31, 2018 | — | = | 100 | × | (413) | ÷ | —) |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 US$ in millions
Comparison to Competitors
Moderna Inc., operating profit margin, long-term trends, comparison to competitors
| Moderna Inc. | AbbVie Inc. | Amgen Inc. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|
| Dec 31, 2022 | 51.10% | 31.21% | 38.57% | 27.17% | 38.93% | 18.69% |
| Dec 31, 2021 | 75.22% | 31.89% | 31.44% | 36.72% | 55.67% | 25.57% |
| Dec 31, 2020 | -381.82% | 24.81% | 37.70% | 16.72% | 42.09% | 24.19% |
| Dec 31, 2019 | — | 39.03% | 43.57% | 19.38% | 28.10% | 17.99% |
| Dec 31, 2018 | — | 19.49% | 45.55% | 37.83% | 37.77% | 15.53% |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).